News | August 06, 2021
Strides to acquire US manufacturing facility of Endo for $24 mn
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Aditya Puri former MD of HDFC bank joins Solara board as chairman
This deal makes Meddo, one of the largest health-tech players in India
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
